Structure-function relationships of inhibition of human cytochromes P450 1A1, 1A2, 1B1, 2C9, and 3A4 by 33 flavonoid derivatives

Chemical Research in Toxicology

Volumn 23, Issue 12, 2010, Pages 1921-1935

  Shimada, Tsutomu ^a   Tanaka, Katsuhiro ^a   Takenaka, Shigeo ^a   Murayama, Norie ^b   Martin, Martha V ^c   Foroozesh, Maryam K ^d   Yamazaki, Hiroshi ^b   Guengerich, F Peter ^c   Komori, Masayuki ^a  

^a Osaka Prefecture University   (Japan)

^b SHOWA PHARMACEUTICAL UNIVERSITY   (Japan)

^c VANDERBILT UNIVERSITY   (United States)

^d XAVIER UNIVERSITY OF LOUISIANA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 HYDROXYFLAVONE; 7 HYDROXYFLAVONE; ACACETIN; ALPHA NAPHTHOFLAVONE; APIGENIN; AURANTIIN; BAICALEIN; BETA NAPHTHOFLAVONE; CHRYSIN; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; CYTOCHROME P450 1B1; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; ETHOXYRESORUFIN; FLAVANONE; FLAVONE; FLAVONE DERIVATIVE; GALANGIN; GENISTEIN; KAEMPFEROL; MIDAZOLAM; NARINGENIN; PRIMULETIN; QUERCETIN; RESORUFIN;

ARTICLE; CATALYSIS; COMPARATIVE STUDY; ENZYME INHIBITION; HUMAN; HYDROXYLATION; IC 50; MOLECULAR DOCKING; OXIDATION; PROTEIN PROTEIN INTERACTION; STRUCTURE ACTIVITY RELATION;

ARYL HYDROCARBON HYDROXYLASES; BINDING SITES; COMPUTER SIMULATION; CYTOCHROME P-450 CYP1A1; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; FLAVONOIDS; HUMANS; KINETICS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 78650456545     PISSN: 0893228X     EISSN: 15205010     Source Type: Journal    
DOI: 10.1021/tx100286d     Document Type: Article

References (47)

1. Arct, J. and Pytkowska, K. (2008) Flavonoids as components of biologically active cosmeceuticals Clin. Dermatol. 26, 347-357
2. Kale, A., Gawande, S., and Kotwal, S. (2008) Cancer phytotherapeutics: role for flavonoids at the cellular level Phytother. Res. 22, 567-577
3. Zhang, S., Yang, X., Coburn, R. A., and Morris, M. E. (2005) Structure activity relationships and quantitative structure activity relationships for the flavonoid-mediated inhibition of breast cancer resistance protein Biochem. Pharmacol. 70, 627-639
4. Kim, H.-J., Lee, S. B., Park, S.-K., Kim, H. M., Park, Y. I., and Dong, M.-S. (2005) Effects of hydroxy group numbers on the B-ring of 5,7-dihydroxyflavones on the differential inhibition of human CYP 1A and CYP1B1 enzymes Arch. Pharm. Res. 28, 1114-1121
5. Tsujimoto, M., Horie, M., Honda, H., Takara, K., and Nishiguchi, K. (2009) The structure-activity correlation on the inhibitory effects of flavonoids on cytochrome P450 3A activity Biol. Pharm. Bull. 32, 671-676
6. Walle, T. (2007) Methoxylated flavones, a superior cancer chemopreventive flavonoid subclass? Semin. Cancer Biol. 17, 354-362
7. Walle, U. K. and Walle, T. (2007) Bioavailable flavonoids: cytochrome P450-mediated metabolism of methoxyflavones Drug Metab. Dispos. 35, 1985-1989
8. Moon, Y. J., Wang, X., and Morris, M. E. (2006) Dietary flavonoids: effects on xenobiotic and carcinogen metabolism Toxicol. In Vitro 20, 187-210
9. Breinholt, V. M., Offord, E. A., Brouwer, C., Nielsen, S. E., Brøsen, K., and Friedberg, T. (2002) In vitro investigation of cytochrome P450-mediated metabolism of dietary flavonoids Food Chem. Toxicol. 40, 609-616
10. Hodek, P., Trefil, P., and Stiborová, M. (2002) Flavonoids-potent and versatile biologically active compounds interacting with cytochromes P450 Chem.-Biol. Interact. 139, 1-21
11. Doostdar, H., Burke, M. D., and Mayer, R. T. (2000) Bioflavonoids: Selective substrates and inhibitors for cytochrome P450 CYP1A and CYP1B1 Toxicology 144, 31-38
12. Otake, Y. and Walle, T. (2002) Oxidation of the flavonoids galangin and kaempferide by human liver microsomes and CYP1A1, CYP1A2, and CYP2C9 Drug Metab. Dispos. 30, 103-105
13. Si, D., Wang, Y., Zhou, Y. H., Guo, Y., Wang, J., Zhou, H., Li, Z. S., and Fawcett, J. P. (2008) Mechanism of CYP2C9 inhibition by flavones and flavonols Drug Metab. Dispos. 37, 629-34
14. Zhai, S., Dai, R., Friedman, F. K., and Vestal, R. E. (1998) Comparative inhibition of human cytochromes P450 1A1 and 1A2 by flavonoids Drug Metab. Dispos. 26, 989-992
15. Kimura, Y., Ito, H., Ohnishi, R., and Hatano, T. (2010) Inhibitory effects of polyphenols on human cytochrome P450 3A4 and 2C9 activity Food Chem. Toxicol. 48, 429-435
16. Quintieri, L., Palatini, P., Nassi, A., Ruzza, P., and Floreani, M. (2007) Flavonoids diosmetin and luteolin inhibit midazolam metabolism by human liver microsomes and recombinant CYP 3A4 and CYP3A5 enzymes Biochem. Pharmacol. 75, 1426-1437
17. Roberts, D. W., Doerge, D. R., Churchwell, M. I., Gamboa da Costa, G., Marques, M. M., and Tolleson, W. H. (2004) Inhibition of extrahepatic human cytochromes P450 1A1 and 1B1 by metabolism of isoflavones found in Trifolium pratense (red clover) J. Agric. Food Chem. 52, 6623-6632
18. Guengerich, F. P. (2005) Human cytochrome P450 enzymes. In Cytochrome P450: Structure, Mechanism, and Biochemistry, 3 rd ed. (Ortiz de Montellano, P. R., Ed.) pp 377 - 530, Kluwer Academic/Plenum Press, New York.
19. Shimada, T. (2006) Xenobiotic-metabolizing enzymes involved in activation and inactivation of carcinogenic polycyclic aromatic hydrocarbons Drug Metab. Pharmacokinet. 21, 257-276
20. Guengerich, F. P., Chun, Y.-J., Kim, D., Gillam, E. M. J., and Shimada, T. (2003) Cytochrome P450 1B1: A target for inhibition in anticarcinogenesis strategies Mutat. Res. 523-524, 173-182
21. Walle, T., Ta, N., Kawamori, T., Wen, X., Tsuji, P. A., and Walle, U. K. (2007) Cancer chemopreventive properties of orally bioavailable flavonoids - Methylated versus unmethylated flavones Biochem. Pharmacol. 73, 1288-1296
22. Courter, L. A., Musafia-Jeknic, T., Fischer, K., Bildfell, R., Giovanini, J., Pereira, C., and Baird, W. M. (2007) Urban dust particulate matter alters PAH-induced carcinogenesis by inhibition of CYP1A1 and CYP1B1 Toxicol. Sci. 95, 63-73
23. Shimada, T., Tanaka, K., Takenaka, S., Foroozesh, M. K., Murayama, N., Yamazaki, H., Guengerich, F. P., and Komori, M. (2009) Reverse type I binding spectra of human cytochrome P450 1B1 induced by flavonoid, stilbene, pyrene, naphthalene, phenanthrene, and biphenyl derivatives that inhibit catalytic activity: A structure-function relationship study Chem. Res. Toxicol. 22, 1325-1333
24. McKendall, M. E., Smith, T. P., Anh, K., Ellis, J., McGee, T., Foroozesh, M., Zhu, N., and Klein Stevens, C. (2008) Methoxyflavone inhibitors of cytochrome P450 J. Chem. Crystallogr. 38, 231-237
25. Zhu, N., Lightsey, K., Foroozesh, M., Alworth, W., Chaudhary, A., Willett, K. L., and Klein Stevens, C. L. K. (2006) Naphthoflavone propargyl ether inhibitors of cytochrome P450 J. Chem. Crystallogr. 36, 289-296
26. Shimada, T. and Guengerich, F. P. (2006) Inhibition of human cytochrome P450 1A1-, 1A2-, and 1B1-mediated activation of procarcinogens to genotoxic metabolites by polycyclic aromatic hydrocarbons Chem. Res. Toxicol. 19, 288-294
27. Shimada, T., Murayama, N., Okada, K., Funae, Y., Yamazaki, H., and Guengerich, F. P. (2007) Different mechanisms of inhibition for human cytochrome P450 1A1, 1A2, and 1B1 by polycyclic aromatic inhibitors Chem. Res. Toxicol. 20, 489-496
28. Shimada, T., Murayama, N., Tanaka, K., Takenaka, S., Imai, Y., Hopkins, N. E., Foroozesh, M. K., Alworth, W. L., Yamazaki, H., Guengerich, F. P., and Komori, M. (2008) Interaction of polycyclic aromatic hydrocarbons with human cytochrome P450 1B1 in inhibiting catalytic activity Chem. Res. Toxicol. 21, 2313-2323
29. 5 on xenobiotic oxidations catalyzed by 12 recombinant human cytochrome P450s expressed in membranes of Escherichia coli Protein Expression Purif. 24, 329-337
30. Isin, E. M. and Guengerich, F. P. (2006) Kinetics and thermodynamics of ligand binding by cytochrome P450 3A4 J. Biol. Chem. 281, 9127-9136
31. Krauser, J. A. and Guengerich, F. P. (2005) Cytochrome P450 3A4-catalyzed testosterone 6beta-hydroxylation stereochemistry, kinetic deuterium isotope effects, and rate-limiting steps J. Biol. Chem. 280, 19496-19506
32. Wu, Z. L., Sohl, C. D., Shimada, T., and Guengerich, F. P. (2006) Recombinant enzymes overexpressed in bacteria show broad catalytic specificity of human cytochrome P450 2W1 and limited activity of human cytochrome P450 2S1 Mol. Pharmacol. 69, 2007-2014
33. Yamazaki, H., Inoue, K., Chiba, K., Ozawa, N., Kawai, T., Suzuki, Y., Goldstein, J. A., Guengerich, F. P., and Shimada, T. (1998) Comparative studies on the catalytic roles of cytochrome P450 2C9 and its Cys- and Leu-variants in the oxidation of warfarin, flurbiprofen, and diclofenac by human liver microsomes Biochem. Pharmacol. 56, 243-251
34. Emoto, C., Murayama, N., and Yamazaki, H. (2008) Effects of enzyme sources on midazolam 1′-hydroxylation activity catalyzed by recombinant cytochrome P450 3A4 in combination with NADPH-cytochrome P450 reductase Drug Metab. Lett. 2, 190-192
35. Omura, T. and Sato, R. (1964) The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature J. Biol. Chem. 239, 2370-2378
36. Lowry, O. H., Rosebrough, N. J., Farr, A. L., and Randall, R. J. (1951) Protein measurement with the Folin phenol reagent J. Biol. Chem. 193, 265-275
37. Sansen, S., Yano, J. K., Reynald, R. L., Schoch, G. A., Griffin, K. J., Stout, C. D., and Johnson, E. F. (2007) Adaptations for the oxidation of polycyclic aromatic hydrocarbons exhibited by the structure of human P450 1A2 J. Biol. Chem. 282, 14348-14355
38. Wester, M. R., Yano, J. K., Schoch, G. A., Yang, C., Griffin, K. J., Stout, C. D., and Johnson, E. F. (2004) The structure of human cytochrome P450 2C9 complexed with flurbiprofen at 2.0-A resolution J. Biol. Chem. 279, 35630-35637
39. Yano, J. K., Wester, M. R., Schoch, G. A., Griffin, K. J., Stout, C. D., and Johnson, E. F. (2004) The structure of human microsomal cytochrome P450 3A4 determined by X-ray crystallography to 2.05-Å resolution J. Biol. Chem. 279, 38091-38094
40. Ueng, Y.-F., Kuwabara, T., Chun, Y. J., and Guengerich, F. P. (1997) Cooperativity in oxidations catalyzed by cytochrome P450 3A4 Biochemistry 36, 370-381
41. Niwa, T., Murayama, N., and Yamazaki, H. (2008) Heterotropic cooperativity in oxidation mediated by cytochrome P450 Curr. Drug Metab. 5, 453-462
42. Marechal, J. D., Yu, J., Brown, S., Kapelioukh, I., Rankin, E. M., Wolf, C. R., Roberts, G. C., Paine, M. J., and Sutcliffe, M. J. (2006) In silico and in vitro screening for inhibition of cytochrome P450 CYP3A4 by comedications commonly used by patients with cancer Drug Metab. Dispos. 34, 534-538
43. Fishelovitch, D., Shaik, S., Wolfson, H. J., and Nussinov, R. (2009) Theoretical characterization of substrate access/exit channels in the human cytochrome P450 3A4 enzyme: involvement of phenylalanine residues in the gating mechanism J. Phys. Chem. B 113, 13018-13025
44. Isin, E. M. and Guengerich, F. P. (2006) Kinetics and thermodynamics of ligand binding by cytochrome P450 3A4 J. Biol. Chem. 281, 9127-9136
45. Ekroos, M. and Sjögren, T. (2006) Structural basis for ligand promiscuity in cytochrome P450 3A4 Proc. Natl. Acad. Sci. U.S.A. 103, 13682-13687
46. Torimoto, N., Ishii, I., Hata, M., Nakamura, H., Imada, H., Ariyoshi, N., Ohmori, S., Igarashi, T., and Kitada, M. (2003) Direct interaction between substrates and endogenous steroids in the active site may change the activity of cytochrome P450 3A4 Biochemistry 42, 15068-15077
47. Shimada, T., Iwasaki, M., Martin, M. V., and Guengerich, F. P. (1989) Human liver microsomal cytochrome P-450 enzymes involved in the bioactivation of procarcinogens detected by umu gene response in Salmonella typhimurium TA1535/pSK1002 Cancer Res. 49, 3218-3228